Dec 17, Marr Bio was approved to list on the new OTC market and public transfer.

The note shows, Marr Bio’s revenues from January to June in 2015 is ￥8.77 million, and net profit is ￥1.67 million. The 2014 and 2013 annual revenues of the company are ￥8.46 million and ￥7.23 million, the net profit is ￥-1.08 million and ￥-1.42 million.

Data shows, Marr Bio was established in August 18, 2005. It’s committed to HIV prevention, improvement of HIV testing technology and complete equipment. Main business is developing, manufacturing & selling Noninvasive detection kit.

Marr Bio’s main product is aware HIV-Ab Oral Mucous Exudate Assay Kit which is use for testing HIV-1/2 Ab from people oral mucous exudate.

Northest Securities is Marr bio’s host broker. Bright & Right Attorneys-at-law is legal adviser. Zhongxincai Guanghua CPAs for financial audit.